Elsayed Soliman to Double-Blind Method
This is a "connection" page, showing publications Elsayed Soliman has written about Double-Blind Method.
Connection Strength
0.883
-
Furberg CD, Soliman EZ. Double-blindness protects scientific validity. J Thromb Haemost. 2008 Feb; 6(2):230-1.
Score: 0.278
-
O'Neal WT, Sandesara P, Patel N, Venkatesh S, Samman-Tahhan A, Hammadah M, Kelli HM, Soliman EZ. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging. 2017 Jul 01; 18(7):725-729.
Score: 0.136
-
O'Neal WT, Sandesara PB, Samman-Tahhan A, Kelli HM, Hammadah M, Soliman EZ. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2017 07; 24(11):1212-1219.
Score: 0.134
-
O'Neal WT, Sandesara P, Hammadah M, Venkatesh S, Samman-Tahhan A, Kelli HM, Soliman EZ. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2017 06 01; 119(11):1785-1790.
Score: 0.133
-
Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, Aragón García R, Plummer P, Sabagha N, Pauls Q, Cassarly C, Dillon CR, Di Tullio MR, Hod EA, Soliman EZ, Gladstone DJ, Healey JS, Sharma M, Chaturvedi S, Janis LS, Krishnaiah B, Nahab F, Kasner SE, Stanton RJ, Kleindorfer DO, Starr M, Winder TR, Clark WM, Miller BR, Elkind MSV. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024 Feb 20; 331(7):573-581.
Score: 0.054
-
Tikkanen JT, Soliman EZ, Pester J, Danik JS, Gomelskya N, Copeland T, Lee IM, Buring JE, Manson JE, Cook NR, Albert CM. A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles. Sci Rep. 2023 Jul 15; 13(1):11454.
Score: 0.052
-
Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, Simpson LM, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol. 2017 Dec; 10(12).
Score: 0.035
-
Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. J Natl Med Assoc. 2018 Aug; 110(4):343-351.
Score: 0.034
-
Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014 Oct 15; 114(8):1217-22.
Score: 0.028